VYNE Therapeutics (NASDAQ:VYNE) Posts Quarterly Earnings Results, Misses Expectations By $3.33 EPS

VYNE Therapeutics (NASDAQ:VYNE) released its quarterly earnings data on Thursday. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33), FiscalAI reports. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

VYNE Therapeutics Stock Performance

Shares of VYNE traded down $0.23 during mid-day trading on Thursday, reaching $28.32. 93,278 shares of the company were exchanged, compared to its average volume of 44,151. VYNE Therapeutics has a 52 week low of $14.03 and a 52 week high of $79.75. The stock has a market capitalization of $18.98 million, a PE ratio of -74.54 and a beta of 2.00. The business has a 50 day simple moving average of $32.72 and a two-hundred day simple moving average of $31.48.

VYNE Therapeutics Dividend Announcement

The business also recently declared a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were paid a $19.00 dividend.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of VYNE Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in VYNE Therapeutics during the 4th quarter worth approximately $46,000. Two Sigma Investments LP acquired a new position in shares of VYNE Therapeutics in the 3rd quarter worth approximately $74,000. Geode Capital Management LLC boosted its stake in shares of VYNE Therapeutics by 64.2% in the 4th quarter. Geode Capital Management LLC now owns 225,152 shares of the company’s stock valued at $131,000 after purchasing an additional 88,030 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of VYNE Therapeutics in the 4th quarter valued at $147,000. Finally, Shay Capital LLC acquired a new stake in shares of VYNE Therapeutics during the third quarter worth $165,000. 83.78% of the stock is currently owned by institutional investors.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.